Genflow Biosciences PLC Announces Holding(s) in Company
Genflow Biosciences PLC (GENFF) reported a significant change in shareholding as Jonathan Mark Swann increased his voting rights in the company. The shareholder's position increased to 8.4% of total voting rights, up from the previous 7.01%, representing 36,588,550 voting rights.
The notification, filed on September 19, 2025, indicates the change occurred through direct acquisition of shares, with no financial instruments or indirect voting rights involved. The transaction was completed in London and reported in accordance with UK regulatory requirements.
["Increased stake by major shareholder indicates confidence in company", "Voting rights increased by 1.39 percentage points to 8.4%"]Genflow Biosciences PLC (GENFF) ha registrato un significativo cambiamento nel capitale sociale, poiché Jonathan Mark Swann ha aumentato i suoi diritti di voto nell'azienda. La partecipazione dell'azionista è salita all'8,4% dei diritti di voto totali, rispetto al 7,01% precedente, pari a 36.588.550 diritti di voto.
La comunicazione, depositata il 19 settembre 2025, indica che l'aumento è avvenuto tramite acquisizione diretta di azioni, senza strumenti finanziari o diritti di voto indiretti coinvolti. L'operazione è stata completata a Londra e riportata in conformità ai requisiti regolamentari del Regno Unito.
Genflow Biosciences PLC (GENFF) registró un cambio significativo en la participación, ya que Jonathan Mark Swann incrementó sus derechos de voto en la empresa. La posición del accionista subió a 8,4% del total de derechos de voto, desde el tramo anterior del 7,01%, equivalente a 36.588.550 derechos de voto.
La notificación, presentada el 19 de septiembre de 2025, indica que el cambio se produjo mediante adquisición directa de acciones, sin instrumentos financieros ni derechos de voto indirectos involucrados. La operación se llevó a cabo en Londres y se comunicó de acuerdo con los requisitos regulatorios del Reino Unido.
Genflow Biosciences PLC (GENFF)는 조나단 마크 스완이 회사의 의결권을 증가시키면서 주주 지분에 중요한 변화를 보고했다. 주주의 지분은 총 의결권의 8.4%로 증가했고, 이전의 7.01%에서 상승하며 의결권 36,588,550에 해당한다.
공시는 2025년 9월 19일에 제출됐고, 변화가 주식의 직접 매수를 통해 발생했으며 금융 상품이나 간접 의결권은 관련되지 않았음을 나타낸다. 거래는 런던에서 완료되었고 영국 규제 요건에 따라 보고되었다.
Genflow Biosciences PLC (GENFF) a enregistré un changement significatif de participation alors que Jonathan Mark Swann a augmenté ses droits de vote dans l'entreprise. La participation de l'actionnaire est passée à 8,4% du total des droits de vote, contre 7,01% auparavant, soit 36 588 550 droits de vote.
La notification, déposée le 19 septembre 2025, indique que le changement est intervenu par acquisition directe d'actions, sans instruments financiers ni droits de vote indirects impliqués. L'opération a été effectuée à Londres et déclarée conformément aux exigences réglementaires du Royaume-Uni.
Genflow Biosciences PLC (GENFF) meldete eine erhebliche Änderung der Aktionärsstruktur, da Jonathan Mark Swann seine Stimmrechte im Unternehmen erhöht hat. Die Position des Aktionärs stieg auf 8,4% der gesamten Stimmrechte, gegenüber dem vorherigen Stand von 7,01%, was 36.588.550 Stimmrechten entspricht.
Die Meldung, eingereicht am 19. September 2025, weist darauf hin, dass die Veränderung durch direkten Erwerb von Aktien erfolgt ist, ohne Finanzinstrumente oder indirekte Stimmrechte. Die Transaktion wurde in London abgeschlossen und gemäß den britischen regulatorischen Anforderungen gemeldet.
Genflow Biosciences PLC (GENFF) أبلغت عن تغيير كبير في حصة الملكية حيث زاد جوناثان مارك سوان من حقوق تصويته في الشركة. بلغت حصة المساهم 8.4% من إجمالي حقوق التصويت، مرتفعة من 7.01% السابقة، ما يعادل 36,588,550 حق تصويت.
تشير الإخطار المقدم في 19 سبتمبر 2025 إلى أن التغيير حدث من خلال الاستحواذ المباشر على الأسهم، دون أدوات مالية أو حقوق تصويت غير مباشرة. تم إتمام الصفقة في لندن وتم الإبلاغ عنها وفقاً للمتطلبات التنظيمية في المملكة المتحدة.
Genflow Biosciences PLC (GENFF) 报告称股权发生重大变动，Jonathan Mark Swann 增加了在公司的表决权。股东的持股已增至总表决权的8.4%，高于先前的7.01%，相当于36,588,550张表决权。
提交的通知显示，变动通过直接收购股票实现，未涉及金融工具或间接表决权。交易在伦敦完成，并按英国监管要求进行了披露。
- None.
- None.
LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BP2C3V08 |
Issuer Name
GENFLOW BIOSCIENCES PLC |
UK or Non-UK Issuer
UK |
2. Reason for Notification
An acquisition or disposal of voting rights |
3. Details of person subject to the notification obligation
Name
Jonathan Mark Swann |
City of registered office (if applicable)
rickmansworth |
Country of registered office (if applicable)
United Kingdom |
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
19-Sep-2025 |
6. Date on which Issuer notified
19-Sep-2025 |
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
Resulting situation on the date on which threshold was crossed or reached | 8.400000 | 0.000000 | 8.400000 | 36588550 |
Position of previous notification (if applicable) | 7.010000 | 0.000000 | 7.010000 | 31788550 |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 | 36588550 | 0 | 8.400000 | 0.000000 |
Sub Total 8.A | 36588550 | |||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Sub Total 8.B1 | ||||
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
Sub Total 8.B2 | |||||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. |
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
NONE |
12. Date of Completion
19-Sep-2025 |
13. Place Of Completion
London |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is Jonathan Mark Swann's new stake in Genflow Biosciences (GENFF)?
When did Jonathan Mark Swann increase his holdings in GENFF?
How many voting rights does Jonathan Mark Swann hold in Genflow Biosciences?
What type of voting rights does Jonathan Mark Swann hold in GENFF?
